Protease inhibitor

Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:20am

The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.

Key Points: 
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The global antiretroviral therapy market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
  • The report provides a comprehensive analysis of the global antiretroviral therapy market with potential impact of COVID-19.

Outlook on the Worldwide Anti-viral Drug Industry to 2025 - Major Players and Strategy Analysis - ResearchAndMarkets.com

Wednesday, May 20, 2020 - 2:23pm

The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world.

Key Points: 
  • The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world.
  • The increasing influenza prevalence around the world is a second major reason for the increasing demand for anti-viral drugs around the world.
  • On the basis of application type, the global anti-viral drug market is segmented by herpes antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, influenza antiviral drugs, and other antiviral drugs.
  • The global anti-viral drug market segmentation based on the mechanism of action is done by nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others.

Technological Advances in the Anti-Viral Drug Therapy Market to Aid Treatment of COVID-19 Patients, Reports TBRC

Thursday, May 14, 2020 - 4:30pm

Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.

Key Points: 
  • Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.
  • The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of the anti-viral drugs market.
  • Increasing public-private funding for life science research globally is also expected to drive the growth of the global anti-viral drug therapy market.
  • Request A Free Sample Of The Anti-Viral Drug Therapy Market Report:
    The anti-viral drug therapy market is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Tuesday, May 12, 2020 - 12:30pm

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020 at 9:45 a.m.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020 at 9:45 a.m.
  • A live webcast of the fireside chat will be accessible by visiting the Events and Presentations section on the Investors page of Enantas website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection.

Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action

Wednesday, April 22, 2020 - 1:05pm

We are pleased to be expanding our agreement with KSURF as we move forward with our ongoing COVID-19 development program.

Key Points: 
  • We are pleased to be expanding our agreement with KSURF as we move forward with our ongoing COVID-19 development program.
  • The additional compounds from this new license agreement represent a class of compounds called protease inhibitors to potentially treat COVID-19.
  • Cocrystal intends to pursue research and development of these antiviral compounds for coronavirus, including preclinical and clinical development.
  • This license significantly expands and further advances the Company's COVID-19 program by providing more targeted, potent compounds for further development.

DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease

Thursday, April 16, 2020 - 7:00am

Vivoryon Therapeutics AG: Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease

Key Points: 
  • Vivoryon Therapeutics AG: Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease
    The issuer is solely responsible for the content of this announcement.
  • Under the guidance of PD Dr. Stephan Schilling, the Department of Drug Design and Target Validation will work together with Vivoryon to advance first-in-class small molecule meprin inhibitors.
  • The metal-dependent proteases, meprin alpha and meprin beta, are emerging targets in kidney protection, fibrotic diseases, cancer and Alzheimer's disease.
  • By working with Dr. Schilling and his team we are set to advance meprin inhibitors very quickly towards clinical testing in indications like fibrotic diseases or cancer."

KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

Tuesday, March 10, 2020 - 11:30am

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal third quarter ended January 31, 2020.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal third quarter ended January 31, 2020.
  • Third Quarter and Recent Business Highlights:
    Announced results of the Phase 2 trial of KVD001, an intravitreal candidate for treatment of diabetic macular edema (DME).
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.
  • Examples of forward-looking statements include, among others, available funding, our cash runway, potential future clinical trial timing and results.

Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite

Wednesday, March 4, 2020 - 11:45am

We are excited about the potential of novel dual inhibitors of PMIX and PMX as potential drugs for the treatment and prevention of malaria infection.

Key Points: 
  • We are excited about the potential of novel dual inhibitors of PMIX and PMX as potential drugs for the treatment and prevention of malaria infection.
  • In this preclinical research, scientists from Merck and the Walter and Eliza Hall Institute of Medical Research and the Swiss Tropical and Public Health Institute in Basel, screened a targeted library of protease inhibitors that kill the P. falciparum parasite.
  • For more than 80 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases.
  • The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

KalVista Pharmaceuticals Provides Business Update

Wednesday, November 13, 2019 - 12:30pm

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the status of its development programs.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the status of its development programs.
  • KalVista now expects to complete enrollment for the KVD900 Phase 2 clinical trial before year-end 2019 and to provide data in 2020.
  • We are pleased with the rate of enrollment of our Phase 2 clinical trial of KVD900 in HAE patients, said Andrew Crockett, Chief Executive Officer of KalVista.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

Global Antiretroviral Market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 - 2023

Wednesday, April 17, 2019 - 9:18pm

The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others).

Key Points: 
  • The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others).
  • However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth.
  • Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017.
  • Global Antiretroviral Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.